PTC THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.36 USD | +1.54% |
|
-2.26% | +31.93% |
| May. 24 | Ptc Therapeutics Insider Sold Shares Worth $764,800, According to a Recent SEC Filing | MT |
| May. 21 | Goldman Sachs Adjusts PTC Therapeutics Price Target to $32 From $18, Maintains Sell Rating | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,960 | 4,164 | 2,816 | 2,786 | 2,080 | 2,789 | - | - |
| Enterprise Value (EV) 1 | 2,986 | 3,393 | 2,474 | 2,947 | 1,487 | 2,285 | 2,365 | 2,262 |
| P/E ratio | -11.2 x | -9.19 x | -5.36 x | -4.9 x | -3.29 x | -7.23 x | -13.7 x | -52.6 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 9.64 x | 10.9 x | 5.23 x | 3.99 x | 2.22 x | 3.67 x | 3.3 x | 2.96 x |
| EV / Revenue | 9.73 x | 8.91 x | 4.59 x | 4.22 x | 1.59 x | 3.01 x | 2.8 x | 2.4 x |
| EV / EBITDA | - | -12 x | -7.97 x | -9.25 x | -7.33 x | -50.3 x | 28.5 x | 13.1 x |
| EV / FCF | -26.6 x | -16 x | -8.85 x | -7.58 x | -7.96 x | -41.5 x | 26.9 x | 9.05 x |
| FCF Yield | -3.76% | -6.25% | -11.3% | -13.2% | -12.6% | -2.41% | 3.72% | 11.1% |
| Price to Book | 5.01 x | 8.36 x | 1,952 x | -7.89 x | -2.55 x | -2.76 x | -2.78 x | -3.24 x |
| Nbr of stocks (in thousands) | 61,631 | 68,236 | 70,698 | 72,991 | 75,463 | 76,697 | - | - |
| Reference price 2 | 48.03 | 61.03 | 39.83 | 38.17 | 27.56 | 36.36 | 36.36 | 36.36 |
| Announcement Date | 3/2/20 | 2/25/21 | 2/22/22 | 2/21/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 307 | 380.8 | 538.6 | 698.8 | 937.8 | 760.4 | 844.2 | 942.6 |
| EBITDA 1 | - | -282.7 | -310.3 | -318.6 | -202.9 | -45.4 | 83.1 | 172.3 |
| EBIT 1 | -241.2 | -326.2 | -374.4 | -447.4 | -439.5 | -215.8 | -28 | 85.61 |
| Operating Margin | -78.56% | -85.66% | -69.52% | -64.03% | -46.86% | -28.38% | -3.32% | 9.08% |
| Earnings before Tax (EBT) 1 | -239.9 | -402.9 | -518.3 | -587.5 | -696.1 | -393.5 | -242.4 | -65.53 |
| Net income 1 | -251.6 | -438.2 | -523.9 | -559 | -626.6 | -384.5 | -186.8 | -57.19 |
| Net margin | -81.95% | -115.07% | -97.27% | -80% | -66.81% | -50.56% | -22.12% | -6.07% |
| EPS 2 | -4.270 | -6.640 | -7.430 | -7.790 | -8.370 | -5.028 | -2.661 | -0.6907 |
| Free Cash Flow 1 | -112.4 | -211.9 | -279.5 | -388.7 | -186.9 | -55 | 88 | 250 |
| FCF margin | -36.61% | -55.65% | -51.9% | -55.62% | -19.92% | -7.23% | 10.42% | 26.52% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 105.89% | 145.13% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/2/20 | 2/25/21 | 2/22/22 | 2/21/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 165.2 | 148.7 | 165.5 | 217.1 | 167.4 | 220.4 | 213.8 | 196.6 | 307.1 | 210.1 | 183.4 | 165.1 | 198.7 | 135 | 197.6 |
| EBITDA | - | -60.21 | - | - | - | -74.79 | -158.5 | - | 86.52 | - | - | - | - | - | - |
| EBIT 1 | -84.73 | -86.52 | -92.36 | -68.19 | -200.3 | -117.6 | -209.5 | -118.2 | 5.82 | -45.45 | -50.9 | -76.18 | -41.51 | -41.08 | 22.8 |
| Operating Margin | -51.28% | -58.17% | -55.8% | -31.4% | -119.67% | -53.37% | -98.01% | -60.11% | 1.9% | -21.63% | -27.75% | -46.15% | -20.89% | -30.43% | 11.54% |
| Earnings before Tax (EBT) 1 | -138.6 | -121.9 | -148.7 | -127.2 | -189.7 | -135 | -237.5 | -166.6 | -157.1 | -84.7 | -88.44 | -119.1 | -101.2 | - | - |
| Net income 1 | -143.3 | -126.7 | -152.1 | -109.3 | -170.9 | -139 | -198.9 | -133 | -155.8 | -91.58 | -86.25 | -112.2 | -96.46 | -39.3 | -7.7 |
| Net margin | -86.71% | -85.2% | -91.88% | -50.35% | -102.08% | -63.05% | -93.02% | -67.64% | -50.74% | -43.58% | -47.03% | -67.95% | -48.55% | -29.11% | -3.9% |
| EPS 2 | -2.030 | -1.780 | -2.130 | -1.530 | -2.350 | -1.880 | -2.660 | -1.760 | -2.060 | -1.200 | -1.070 | -1.462 | -1.421 | -1.130 | -0.6600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/22/22 | 5/3/22 | 8/4/22 | 10/27/22 | 2/21/23 | 4/27/23 | 8/3/23 | 10/26/23 | 2/29/24 | 4/25/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 25.8 | - | - | 161 | - | - | - | - |
| Net Cash position 1 | - | 771 | 342 | - | 593 | 503 | 424 | 527 |
| Leverage (Debt/EBITDA) | - | - | - | -0.5054 x | - | - | - | - |
| Free Cash Flow 1 | -112 | -212 | -280 | -389 | -187 | -55 | 88 | 250 |
| ROE (net income / shareholders' equity) | -53.2% | -81.4% | -217% | - | - | - | - | - |
| ROA (Net income/ Total Assets) | -18.3% | -22.9% | -25.3% | -30.7% | -23.4% | -22.8% | -4.43% | 22.1% |
| Assets 1 | 1,372 | 1,916 | 2,073 | 1,822 | 2,676 | 1,685 | 4,214 | -259.2 |
| Book Value Per Share 2 | 9.600 | 7.300 | 0.0200 | -4.840 | -10.80 | -13.20 | -13.10 | -11.20 |
| Cash Flow per Share 2 | -1.680 | -2.940 | -3.570 | -4.970 | -2.120 | -1.880 | -1.190 | - |
| Capex 1 | 13.8 | 17.8 | 28.2 | 32 | 28.4 | 27 | 32.8 | 29.3 |
| Capex / Sales | 4.48% | 4.69% | 5.24% | 4.58% | 3.03% | 3.55% | 3.88% | 3.1% |
| Announcement Date | 3/2/20 | 2/25/21 | 2/22/22 | 2/21/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
36.36
USD
Average target price
36.73
USD
Spread / Average Target
+1.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.93% | 2.79B | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- PTCT Stock
- Financials PTC Therapeutics, Inc.
